BTIG Research Cuts Tvardi Therapeutics (NASDAQ:TVRD) Price Target to $5.00

Tvardi Therapeutics (NASDAQ:TVRD) had its price target lowered by analysts at BTIG Research to $5.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target would suggest a potential upside of 145.82% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the stock. Piper Sandler upgraded shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price target for the company in a research report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a report on Wednesday, July 8th. Wall Street Zen downgraded Tvardi Therapeutics to a “strong sell” rating in a research report on Saturday, July 18th. Finally, HC Wainwright began coverage on Tvardi Therapeutics in a report on Monday, June 8th. They issued a “buy” rating and a $9.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tvardi Therapeutics Trading Down 5.0%

Shares of TVRD traded down $0.11 during trading hours on Thursday, reaching $2.03. The company had a trading volume of 231,818 shares, compared to its average volume of 1,031,862. The firm has a 50 day simple moving average of $2.82 and a 200-day simple moving average of $3.41. The company has a market capitalization of $19.08 million, a price-to-earnings ratio of -0.65 and a beta of 0.39. Tvardi Therapeutics has a 12-month low of $1.50 and a 12-month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). Sell-side analysts forecast that Tvardi Therapeutics will post -2.32 earnings per share for the current year.

Institutional Trading of Tvardi Therapeutics

Several large investors have recently modified their holdings of the business. Arax Advisory Partners increased its stake in shares of Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after purchasing an additional 6,173 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in Tvardi Therapeutics in the 2nd quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Tvardi Therapeutics during the 2nd quarter valued at $43,000. HRT Financial LP acquired a new stake in Tvardi Therapeutics during the 4th quarter valued at $47,000. Finally, XTX Topco Ltd purchased a new position in Tvardi Therapeutics during the fourth quarter worth $55,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.